€27.10
0.88% today
Amsterdam, Aug 12, 05:13 pm CET
ISIN
BE0003818359
Symbol
GLPG

Galapagos Stock price

€27.34
+1.28 4.91% 1M
+5.00 22.38% 6M
+0.82 3.09% YTD
+4.94 22.05% 1Y
-25.64 48.40% 3Y
-132.01 82.84% 5Y
-26.98 49.67% 10Y
+19.50 248.72% 20Y
Amsterdam, Closing price Mon, Aug 11 2025
-0.66 2.36%
ISIN
BE0003818359
Symbol
GLPG
Industry

Key metrics

Basic
Market capitalization
€1.8b
Enterprise Value
€-1.2b
Net debt
positive
Cash
€3.1b
Shares outstanding
65.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.7 | 6.7
EV/Sales
negative | negative
EV/FCF
4.2
P/B
0.7
Financial Health
Equity Ratio
70.1%
Return on Equity
2.6%
ROCE
-9.7%
ROIC
-101.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
€275.6m | €274.4m
EBITDA
€-250.8m | €-206.2m
EBIT
€-332.8m | €-189.7m
Net Income
€-284.3m | €-72.6m
Free Cash Flow
€-298.0m
Growth (TTM | estimate)
Revenue
-52.5% | -0.5%
EBITDA
-95.9% | -97.6%
EBIT
-75.3% | -24.0%
Net Income
-184.4% | -198.0%
Free Cash Flow
34.9%
Margin (TTM | estimate)
Gross
87.6%
EBITDA
-91.0% | -75.2%
EBIT
-120.7%
Net
-103.1% | -26.5%
Free Cash Flow
-108.1%
More
EPS
€-4.3
FCF per Share
€-4.5
Short interest
-
Employees
704
Rev per Employee
€390.0k
Show more

Is Galapagos a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Galapagos Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Galapagos forecast:

2x Buy
12%
6x Hold
35%
9x Sell
53%

Analyst Opinions

17 Analysts have issued a Galapagos forecast:

Buy
12%
Hold
35%
Sell
53%

Financial data from Galapagos

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
276 276
53% 53%
100%
- Direct Costs 34 34
38% 38%
12%
241 241
10% 10%
88%
- Selling and Administrative Expenses 145 145
34% 34%
53%
- Research and Development Expense 468 468
9% 9%
170%
-251 -251
96% 96%
-91%
- Depreciation and Amortization 82 82
33% 33%
30%
EBIT (Operating Income) EBIT -333 -333
75% 75%
-121%
Net Profit -284 -284
184% 184%
-103%

In millions EUR.

Don't miss a Thing! We will send you all news about Galapagos directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galapagos Stock News

Neutral
GlobeNewsWire
5 days ago
Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its  Board of Directors created 1,800,000 subscription rights under a new subscription right plan.
Neutral
GlobeNewsWire
6 days ago
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FDA) has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).
Neutral
GlobeNewsWire
20 days ago
Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium ; July 23, 2025, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO...
More Galapagos News

Company Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Head office Belgium
CEO Henry Gosebruch
Employees 704
Founded 1999
Website www.glpg.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today